Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
REGULATED INFORMATION New clinical studies for JETREA® confirm positive OASIS results: 28 days post injection resolution rates ranging from around 40% to 58% New JETREA® ready-diluted formulation...
-
Company receives € 0.6 million research grant from IWT, the Flemish Agency for Innovation by Science and Technology Leuven, April 23, 2015 - ThromboGenics NV (Euronext Brussels: THR), an...
-
Oncurious NV to develop TB-403 for Pediatric Brain Tumors Leuven, April 14, 2015 - ThromboGenics NV (Euronext Brussels: THR), an integrated biopharmaceutical company focused on developing and...
-
ThromboGenics Announces Positive Topline Results from OASIS Study OASIS Study Meets Primary Endpoint with 41.7% of Patients Treated with JETREA® achieving VMA resolution at Day 28 post injection...
-
OASIS Study Meets Primary Endpoint with 41.7% of Patients Treated with JETREA® achieving VMA resolution at Day 28 post injection (p<0.001) 24 month safety data in line with JETREA® approved label...
-
Leuven, March 16, 2015 - ThromboGenics NV (Euronext Brussels: THR), an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines, today announces...
-
Financial Total revenues of €13.8 million in 2014 (2013 - €112.8 million, including €90 million in milestone payments from Alcon) US sales of JETREA® (ocriplasmin) in 2014 reached €8.8...
-
Leuven, Belgium - 05 March, 2015 - ThromboGenics NV (Euronext Brussels: THR), an integrated biopharmaceutical company focused on developing and commercializing innovative medicines for the treatment...
-
Leuven, March 2, 2015 - ThromboGenics NV (Euronext Brussels: THR), an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines, today announces...
-
Leuven, Belgium - 5 February, 2015 - ThromboGenics NV (Euronext Brussels: THR), an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines,...